<DOC>
	<DOCNO>NCT01357980</DOCNO>
	<brief_summary>The purpose study determine efficacy safety single dose 750 U Dysport compare placebo improvement daily incontinence episode frequency administration mode subject suffer neurogenic detrusor overactivity follow spinal cord injury multiple sclerosis .</brief_summary>
	<brief_title>Neurogenic Detrusor Overactivity Following Spinal Cord Injury Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Subject , family member care giver willing able perform clean intermittent catheterisation ( CIC ) duration study Inadequate response refractory anticholinergic medication Botulinum Toxin naive intradetrusor injection previous treatment Botulinum Toxin type , within 3 month prior study entry condition Have minimum 2 incontinence per day calculate average daily incontinence episode frequency ( IEF ) 3 day precede baseline visit Significant Baseline renal and/or urinary tract pathology Previous treatment endovesical pharmacology agent include detrusor Botulinum Toxin injection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Detrusor Muscle Overactivity</keyword>
</DOC>